Answers are grounded in this paper and cite their sources.
Micafungin (FK-463), a member of the new candin family of antifungal agents, was highly active against clinical isolates of Candida albicans and Candida dubliniensis. The in vitro activity of micafungin suggested that it was more potent than fluconazole, flucytosine, amphotericin B or voriconazole against C. albicans, and comparable or moderately less effective against C. dubliniensis isolates when high-resolution medium (HR) was used. Lower MICs of micafungin were recorded when RPMI 2% or AM3 2% media were used, indicating an influence of the growth medium on the MIC.
No takes yet. Share an insight, caveat, or question.
F.‐M. C. Müller (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: